Compare BCIC & THAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BCIC | THAR |
|---|---|---|
| Founded | 2006 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 162.3M | 193.3M |
| IPO Year | N/A | 2022 |
| Metric | BCIC | THAR |
|---|---|---|
| Price | $12.30 | $4.12 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 65.1K | ★ 1.4M |
| Earning Date | 03-05-2026 | 03-25-2026 |
| Dividend Yield | ★ 15.56% | N/A |
| EPS Growth | ★ 330.32 | N/A |
| EPS | ★ 1.64 | N/A |
| Revenue | ★ $58,080,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $14.87 | N/A |
| P/E Ratio | $7.45 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $11.12 | $0.95 |
| 52 Week High | $17.51 | $9.08 |
| Indicator | BCIC | THAR |
|---|---|---|
| Relative Strength Index (RSI) | 47.16 | 56.35 |
| Support Level | $12.11 | $3.85 |
| Resistance Level | $12.38 | $5.83 |
| Average True Range (ATR) | 0.24 | 0.53 |
| MACD | -0.01 | 0.06 |
| Stochastic Oscillator | 30.77 | 46.47 |
BCP Investment Corp is a closed-end, externally managed, non-diversified management investment company. The company invests in performing, well- established middle market businesses that operate across a wide range of industries. It employs fundamental credit analysis, targeting investments in businesses with relatively low levels of cyclicality and operating risk.
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.